The Fall 2025 Prime Therapeutics Report delivers a comprehensive look at the evolving oncology landscape—from rising cancer rates in younger populations to the expanding role of radiopharmaceuticals and cellular therapies.

Inside this issue:

• Radiopharmaceuticals: Utilization trends, payer strategies and pipeline forecasts
• Early-onset cancer: Incidence spikes, screening shifts and survivorship planning
• Cellular therapy: First approvals for solid tumors and payer cost management
• Bispecific antibodies: Tocilizumab prophylaxis and toxicity management
• Accelerated approvals: Traditional approvals, withdrawals and payer impact
• Multiple myeloma: Brief update, new approvals and pipeline outlook

Whether you're a managed care executive, clinician or pharmacy leader, this report offers actionable insights to help you navigate high-cost therapies, optimize site-of-care strategies and improve patient outcomes.

Read the full report 

Subscribe for Future Issues